Roundview Capital LLC Invests $283,000 in Becton, Dickinson and Company (BDX)

Roundview Capital LLC purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,450 shares of the medical instruments supplier’s stock, valued at approximately $283,000.

Other large investors have also modified their holdings of the company. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and during the 1st quarter worth approximately $105,000. Parkside Financial Bank & Trust boosted its stake in Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares during the last quarter. QCI Asset Management Inc. NY boosted its stake in Becton, Dickinson and by 9.2% during the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares during the last quarter. Finally, Harfst & Associates Inc. boosted its stake in Becton, Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the last quarter. Institutional investors own 87.12% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/10/18/roundview-capital-llc-invests-283000-in-becton-dickinson-and-company-bdx.html.

Several research firms recently weighed in on BDX. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company reissued an “outperform” rating and set a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Barclays PLC reissued an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, July 17th. Finally, Wells Fargo & Company began coverage on shares of Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton, Dickinson and has an average rating of “Buy” and an average target price of $200.93.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total transaction of $941,253.60. Following the sale, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 75,904 shares of company stock valued at $15,242,688. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) opened at 203.07 on Wednesday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The company has a market cap of $46.21 billion, a price-to-earnings ratio of 58.81 and a beta of 1.05. The firm has a 50-day moving average of $197.13 and a 200-day moving average of $193.13.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.35 EPS. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share

Other large investors have also modified their holdings of the company. Almanack Investment Partners LLC. bought a new position in Becton, Dickinson and during the 1st quarter worth approximately $105,000. Parkside Financial Bank & Trust boosted its stake in Becton, Dickinson and by 1.4% during the 1st quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares during the last quarter. QCI Asset Management Inc. NY boosted its stake in Becton, Dickinson and by 9.2% during the 1st quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares during the last quarter. Finally, Harfst & Associates Inc. boosted its stake in Becton, Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the last quarter. Institutional investors own 87.12% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/10/18/roundview-capital-llc-invests-283000-in-becton-dickinson-and-company-bdx.html.

Several research firms recently weighed in on BDX. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company reissued an “outperform” rating and set a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Barclays PLC reissued an “equal weight” rating and set a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, July 17th. Finally, Wells Fargo & Company began coverage on shares of Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Becton, Dickinson and has an average rating of “Buy” and an average target price of $200.93.

In other news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the sale, the insider now owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $200.48, for a total transaction of $941,253.60. Following the sale, the executive vice president now directly owns 18,670 shares of the company’s stock, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 75,904 shares of company stock valued at $15,242,688. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (NYSE BDX) opened at 203.07 on Wednesday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The company has a market cap of $46.21 billion, a price-to-earnings ratio of 58.81 and a beta of 1.05. The firm has a 50-day moving average of $197.13 and a 200-day moving average of $193.13.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. The company had revenue of $3.04 billion during the quarter, compared to the consensus estimate of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s quarterly revenue was down 5.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.35 EPS. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 1.44%. The ex-dividend date of this dividend was Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply